Barinthus Biotherapeutics PLC 10-Q quarterly reports

Barinthus Biotherapeutics plc announced its second-quarter 2026 financial results, highlighting reduced operating expenses but continued net losses and a precarious Nasdaq listing status.

Barinthus Biotherapeutics plc reported a significantly reduced net loss for the first quarter of 2026, driven by lower operating expenses, alongside progress in its merger with Clywedog Therapeutics.

Barinthus Biotherapeutics reported a net loss of $14.6 million for Q3 2025, continued progress in its VTP-1000 celiac disease trial, and detailed its pending all-stock merger with Clywedog Therapeutics.

Barinthus Biotherapeutics PLC reported increased net losses for Q2 and H1 2025, driven by foreign exchange losses and professional fees, despite reduced R&D spending due to a strategic pipeline reprioritization towards immunology and inflammation.

Barinthus Biotherapeutics reports a net loss for Q1 2025 while strategically prioritizing its immunology and inflammation pipeline.

Barinthus Biotherapeutics PLC reported its third quarter 2024 financial results, highlighted by a significant increase in revenue due to a milestone payment, while also providing updates on its clinical pipeline and operational activities.

Barinthus Biotherapeutics reported a net loss of $32.5 million for the first half of 2024, while focusing on key pipeline programs.

Barinthus Biotherapeutics reported a net loss of $15.5 million for the first quarter of 2024, while advancing its pipeline of immunotherapeutic candidates.